Investigating treatments to reduce pain when skin is exposed to sunlight - Wesley Research Institute
Wesley Research Institute

This study is testing a potential new treatment for EPP or XLP that increases melanin in the skin, which protects you from sunlight.


Research Objectives





Patient Group

Indication: Erythropoietic Protoporphyria(EPP)or X-Linked Protoporphyria(XLP)

Study location

Wesley Research Institute



Study type

Industry Sponsored
Sponsors: Mitsubishi Tanabe Pharma Development

Lead investigators

  • Prof David Coman

Clinical Trial Coordinator

  • Venita Bali

Technical title

A Phase 3, Multicenter, Open-Label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects with Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP)

About this research project

Erythropoietic Protoporphyria (referred to as“EPP”) or X-Linked Protoporphyria (referred to as “XLP”) are characterized by the accumulation of a molecule named protoporphyrin in the body, which leads to pain when the skin is exposed to sunlight. The purpose of this trial is to investigate whether an experimental drug called MT-7117 (Dersimelagon) is effective and well tolerated in reducing the severity of symptoms of EPP or XLP.


Latest News

Mitsubishi Development announces largest Australian partnership

On Thursday 6 July Wesley Research Institute and Mitsubishi Development signed a new partnership, the largest for Mitsubishi Development in Australia, which will provide significant funding for Navicare over the next two years.
Maureen Stevenson accepting her 2023 Queensland Community Philanthropist of the Year Award

Maureen Stevenson Award

Maureen Stevenson received the 2023 Community Philanthropist of the Year Award at the Queensland Philanthropy Awards (QCF) held at Brisbane Town Hall.
Andrew Barron, Mandy Maysey and Dr Phil Mosley

Australian scientists prove medicinal cannabis can be a lifechanging treatment for people with Tourette Syndrome

Imagine the pain and embarrassment of violent movements and uncontrollable outbursts at school or work…that’s what life was like for Chris Wright (35) before he started a ground-breaking clinical trial of medicinal cannabis.
1 2 3 6
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram